Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
BLIRT S.A. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, indicating separate examination paths.
DICKENS, AMELIA NICOLE is the busiest examiner, with 1 pending matter. Counsel should address each record independently while keeping scientific terminology and descriptions of the claimed biotechnology consistent where the applications share subject matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.7% | +22.5% |
| EIX, EMILY FAY | 1 | 45.9% | +73.9% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.0% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035143 | PRODUCTION AND USE OF A FREEZE-DRIED OR READY-FOR-LYOPHILIZATION HUMAN RNASE INHIBITOR | EIX, EMILY FAY | 8d |
| 18711923 | TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT | DICKENS, AMELIA NICOLE | — |
| 17642697 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | KOROTCHKINA, LIOUBOV G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035143 | PRODUCTION AND USE OF A FREEZE-DRIED OR READY-FOR-LYOPHILIZATION HUMAN RNASE INHIBITOR | EIX, EMILY FAY | 8d |
| 18711923 | TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT | DICKENS, AMELIA NICOLE | — |
| 17642697 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | KOROTCHKINA, LIOUBOV G | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711923 | TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT | DICKENS, AMELIA NICOLE | 1645 | §102§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18035143 | PRODUCTION AND USE OF A FREEZE-DRIED OR READY-FOR-LYOPHILIZATION HUMAN RNASE INHIBITOR | EIX, EMILY FAY | 1653 | §102§103 | Final Rejection | 8d | Pending | May 03, 2023 |
| 17642697 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | KOROTCHKINA, LIOUBOV G | 1653 | §103§112Other | Non-Final OA | — | Pending | Mar 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBLIRT S.A. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.
Amelia Nicole Dickens has the most, with 1 of BLIRT S.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.